PRESS RELEASE
News
-
-
PRESS RELEASE
adesso increases revenue by 26 % to EUR 1.14 billion / Sharp increase in personnel, fixed-price projects and lower licence income weigh down EBITDA in 2023 / Operating earnings set to rise again
adesso SE reports a 26% revenue increase to EUR 1.14 billion in 2023, with a rise in personnel and fixed-price projects impacting EBITDA. Operating earnings expected to improve in 2024 -
-
PRESS RELEASE
Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
Heidelberg Pharma AG announces financial figures and successful business performance in 2023, including efficacy data from HDP-101 clinical trial. New Management Board team and expansion of ADC technology platform -
PRESS RELEASE
Changes in the Board of Directors of Swiss Steel Group
Swiss Steel Holding AG announces changes in the Board of Directors with the immediate resignation of Barend Fruithof and Oliver Streuli, representing PCS Holding AG, due to the major shareholder's decision not to participate in capital increase. Board now consists of 5 members -
-
-
PRESS RELEASE
Avolta adds Cologne Bonn Airport to operational portfolio with award of 17 new stores for ten years, strengthens footprint in Germany
Avolta AG strengthens its presence in Germany by adding 17 new food and beverage stores to Cologne Bonn Airport for ten years, enhancing its contact points with travelers -
PRESS RELEASE
Upstream Works Announces AgentNow Solution for Instant Customer Service On Demand
Upstream Works introduces AgentNow, offering on-demand customer service with personalized, real-time interactions via chat and video for improved customer experience and support. Organizations can tap into contact center agents efficiently through popular communication channels -
PRESS RELEASE
ProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be presented at AACR
ProteinQure announces breakthrough in triple-negative breast cancer treatment through novel Peptide Drug Conjugate with exceptional efficacy in lab experiments
